Immuno-oncology – Endpoints News

Ticker	Current Price	Change	Graph
IBB	107.81	0.91 (0.84%)
XBI	79.78	1.08 (1.34%)

Dragonfly preps clinical takeoff, inking a collaboration pact with MD Anderson

by Amber Tong — on January 16, 2019 09:42 AM EST

Blocking PD-L1 production in mice, UCSF team spotlights preclinical promise of a Pfizer-backed I/O drug

by Amber Tong — on January 16, 2019 07:14 AM EST
Updated: 07:18 AM

Parker-backed cancer scientists shine a light on an emerging pathway in pancreatic cancer

by John Carroll — on January 14, 2019 08:18 AM EST
Updated: January 15, 2019 03:01 PM

‘It’s us against the world’: And George Yancopoulos wants you to know they are beating the world — big time

by John Carroll — on January 9, 2019 10:27 AM EST
Updated: 10:29 AM

After blueprinting R&D hub, AbbVie dishes out $105M for CD39 pact with Tizona’s new CEO from Roche

by Amber Tong — on January 3, 2019 10:27 AM EST

Cash-poor Agenus finds itself a generous partner in Gilead, shares surge

by Natalie Grover — on December 20, 2018 09:02 AM EST
Updated: 09:41 AM

FDA hands AstraZeneca and Merck a snap OK to market Lynparza in frontline ovarian cancer, marking a new standard in treatment

by John Carroll — on December 20, 2018 04:45 AM EST

AstraZeneca wants a do-over on MYSTIC combo data. But a changeup in focus won’t end the death watch on this pairing

by John Carroll — on December 14, 2018 09:37 AM EST

Targeting CD47? UCLA joins bandwagon, with gel to stem tumors from resurfacing

by Endpoints Staff — on December 11, 2018 07:35 AM EST
Updated: 10:35 AM

CRI study highlights CTLA-4’s marquee role in PD-1/L1 combos — despite an increasingly troubled clinical profile

by John Carroll — on November 30, 2018 09:03 AM EST
Updated: 09:10 AM

The number of I/O cancer drugs in the clinic continues to swell at an explosive pace — offering new hope, fresh concerns

by John Carroll — on November 29, 2018 09:09 AM EST
Updated: 09:13 AM

Seeking an edge in the global I/O race, Alphamab Oncology loads up $100M-plus from marquee backers

by Amber Tong — on November 19, 2018 08:23 AM EST
Updated: 08:39 AM

Pfizer, Merck KGaA report their latest setback with checkpoint contender Bavencio

by John Carroll — on November 19, 2018 07:53 AM EST
Updated: 08:11 AM

The sandbox: Parker Institute throws its research muscle behind gene therapy tech for destroying cancer cells

by John Carroll — on November 15, 2018 10:00 AM EST

On the heels of an Eli Lilly deal, NextCure’s hot hand in I/O attracts a $93M trans-Pacific venture round

by John Carroll — on November 13, 2018 06:31 AM EST
Updated: 10:02 AM

Innovent, Eli Lilly cite a new success for their PD-1 in lung cancer, with a likely pioneering approval in China looming

by John Carroll — on November 9, 2018 08:06 AM EST
Updated: 08:17 AM

Gilead throws its weight — and $50M cash — behind Tango’s I/O discovery engine

by Amber Tong — on October 31, 2018 08:58 AM EST
Updated: 11:15 AM

AstraZeneca is paying Innate Pharma at least $242M in near-term cash to sew up rights to monalizumab-plus

by John Carroll — on October 23, 2018 01:59 AM EST
Updated: 04:00 AM

Merck previews an early hit with Keytruda combo for kidney cancer, putting more pressure on rival Bristol-Myers

by John Carroll — on October 19, 2018 06:19 AM EST

SQZ play: Roche doubles down on a $1.37B-plus deal for a new approach to immuno-oncology out of Bob Langer’s lab

by John Carroll — on October 15, 2018 08:30 AM EST

Category: Immuno-oncology